Us Bancorp \De\ Adc Therapeutics Sa Transaction History

Us Bancorp \De\

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 01, 2022	SELL	$5.96 - $14.99 $298 - $749	-50 Reduced 14.29%	300 $2,000
Q1 2022 May 11, 2022	SELL	$13.28 - $20.03 $1,992 - $3,004	-150 Reduced 30.0%	350 $5,000
Q3 2021 Nov 10, 2021	SELL	$20.45 - $30.0 $12,270 - $18,000	-600 Reduced 54.55%	500 $14,000
Q2 2021 Aug 05, 2021	SELL	$20.38 - $27.04 $14,266 - $18,928	-700 Reduced 38.89%	1,100 $27,000
Q1 2021 Apr 28, 2021	BUY	$22.75 - $34.05 $40,950 - $61,289	1,800 New	1,800 $44,000

55M

82.7K

31.5K

Ticker ADCT
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,645,296
Market Cap $155M
Description
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

Stay updated on Us Bancorp \De\ with notifications on news.